Voriconazole 200mg

DRUG4 trials

Sponsors

Samyang Biopharmaceuticals Corporation, First Affiliated Hospital of Zhejiang University, Post Graduate Institute of Medical Education and Research, Chandigarh, University Hospital, Geneva

Conditions

Chronic Pulmonary AspergillosisCryptococcal MeningitisHIV/AIDSHealthySystemic Mycotic Infection

Early Phase 1

Three Induction Treatments on Cryptococcal Meningitis

First Affiliated Hospital of Zhejiang UniversityCryptococcal Meningitis, HIV/AIDS

Start: 2021-01-25End: 2022-12-01Target: 120Updated: 2021-02-02

Phase 1

Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)

CompletedNCT01657201

Samyang Biopharmaceuticals CorporationSystemic Mycotic Infection

Start: 2012-09-30End: 2012-11-30Updated: 2012-12-24

Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status

University Hospital, GenevaHealthy

Start: 2022-04-01End: 2023-08-31Target: 45Updated: 2022-11-03

Phase 3

A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis

CompletedNCT04824417

Post Graduate Institute of Medical Education and Research, ChandigarhChronic Pulmonary Aspergillosis

Start: 2021-03-01End: 2024-05-31Updated: 2024-08-14

Related Papers

Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.

2025-10-29